Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Research in context

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Research in context

Summary: Background: Cabozantinib is approved for previously treated advanced hepatocellular carcinoma (aHCC) and has been investigated in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ). Atezolizumab plus bevacizumab is approved for unresectable or metastatic HCC untreated w...

Full description

Bibliographic Details
Main Authors: Daneng Li, Yohann Loriot, Adam M. Burgoyne, James M. Cleary, Armando Santoro, Daniel Lin, Santiago Ponce Aix, Ignacio Garrido-Laguna, Ramu Sudhagoni, Xiang Guo, Svetlana Andrianova, Scott Paulson
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:EClinicalMedicine
Subjects:
Hepatocellular carcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Cabozantinib
Atezolizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023005539

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023005539

Similar Items